In Vivo Gene Editing Therapeutics Market

According to Stratistics MRC, the Global In Vivo Gene Editing Therapeutics Market is accounted for $0.9 billion in 2026 and is expected to reach $8.2 billion by 2034 growing at a CAGR of 31.8% during the forecast period. The In Vivo Gene Editing Therapeutics Market encompasses advanced therapeutic approaches that modify genetic material directly within patients using programmable gene editing technologies and specialized delivery systems. Increasing investment in genetic medicine, expanding clinical research pipelines, and growing demand for treatments targeting inherited disorders are supporting market development. Advancements in CRISPR-Cas systems, base editing, and lipid nanoparticle delivery enable precise genetic modification. Growing collaboration between biotechnology companies and pharmaceutical manufacturers creates opportunities for next-generation gene editing therapies.

Market Dynamics:

Driver:

Increasing prevalence of genetic disorders and demand for potentially curative therapies

Increasing prevalence of genetic disorders and demand for potentially curative therapies is driving market growth. Conventional treatments for inherited diseases frequently require lifelong medication and may not address underlying genetic abnormalities. In vivo gene editing technologies enable targeted modification of disease-associated genes directly within patients, creating opportunities for durable therapeutic benefits. Growing investment in rare disease research and genetic medicine supports clinical development. Advancements in CRISPR-Cas editing, molecular targeting, and tissue-specific delivery technologies further strengthen pharmaceutical interest in next-generation gene editing treatments.

Restraint:

High development costs and challenges in targeted gene editing delivery

High development costs and challenges in targeted gene editing delivery restrain market growth. In vivo therapeutic editing requires specialized delivery systems capable of transporting gene editing components into specific tissues while maintaining biological stability and acceptable safety profiles. Limited delivery efficiency in certain organs and potential immune responses complicate treatment development. Extensive preclinical validation, long-term safety monitoring, and specialized manufacturing requirements increase research expenditure. Complex regulatory pathways and uncertainty regarding reimbursement may further delay commercialization and broader patient access.

Opportunity:

Expansion of precision gene correction and extrahepatic therapeutic applications

Expansion of precision gene correction and extrahepatic therapeutic applications presents significant growth opportunities. Biotechnology companies are developing base editing, prime editing, and targeted gene insertion technologies to address disease-causing mutations without relying exclusively on conventional DNA cleavage approaches. Advances in lipid nanoparticles, ligand-conjugated delivery systems, and engineered viral vectors may improve access to tissues beyond the liver. Growing investment in neurological, cardiovascular, and metabolic disease research supports innovation. Improvements in editing specificity and delivery efficiency are expected to expand potential therapeutic indications.

Threat:

Off-target genetic modifications and long-term safety uncertainties

Off-target genetic modifications and long-term safety uncertainties pose significant challenges to market development. In vivo gene editing systems may introduce unintended genomic changes, immune reactions, or tissue-specific toxicities that require extensive evaluation. Potential irreversible genetic alterations increase the importance of rigorous preclinical testing and long-term patient monitoring. Regulatory scrutiny surrounding genome editing safety and ethical considerations may complicate clinical development. Competition from conventional gene therapies, RNA therapeutics, and other genetic medicine approaches could further restrict commercialization and investment.

Covid-19 Impact:

The COVID-19 pandemic disrupted in vivo gene editing research through laboratory restrictions, clinical trial delays, and interruptions in specialized biotechnology supply chains. Reduced access to research facilities and clinical sites temporarily affected experimental development and patient enrollment. However, increased investment in genetic medicine, RNA delivery technologies, and advanced biotechnology manufacturing encouraged innovation. Progress in lipid nanoparticle formulation and nucleic acid delivery created opportunities for therapeutic gene editing research. Post-pandemic expansion of biotechnology infrastructure and clinical research capabilities has supported continued development of in vivo gene editing platforms.

The CRISPR-Cas gene editing segment is expected to be the largest during the forecast period

The CRISPR-Cas gene editing segment is expected to account for the largest market share during the forecast period due to extensive research investment, broad therapeutic applicability, and established development of programmable genome editing technologies. CRISPR-Cas systems enable targeted gene disruption and modification across multiple disease indications. Biotechnology companies are advancing clinical programs targeting genetic, cardiovascular, and metabolic disorders. Growing pharmaceutical partnerships and improvements in editing specificity support adoption. Advancements in guide RNA engineering, nuclease optimization, and targeted delivery further strengthen segment development.

The base editing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the base editing segment is predicted to witness the highest growth rate due to increasing interest in precise nucleotide modification without conventional double-strand DNA breaks. Base editing technologies enable targeted conversion of specific DNA bases and may address disease-associated mutations across multiple genetic disorders. Growing clinical research investment and biotechnology partnerships encourage development. Advancements in editor engineering, delivery systems, and editing specificity are expected to improve therapeutic feasibility and accelerate investigation of next-generation gene correction approaches.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to established biotechnology infrastructure, substantial genetic medicine investment, and extensive clinical research activities. The United States leads regional development through specialized gene editing companies, pharmaceutical manufacturers, and academic medical centers conducting advanced therapeutic research. Growing investment in rare disease treatments and precision medicine supports technology development. Collaboration among biotechnology developers, research institutions, and pharmaceutical companies further strengthens regional opportunities for in vivo gene editing therapeutics.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding biotechnology research activities, increasing investment in genetic medicine, and growing development of advanced therapeutic technologies. China, Japan, South Korea, and India are strengthening gene editing research capabilities and clinical development infrastructure. Government-supported biotechnology initiatives and expanding pharmaceutical partnerships encourage innovation. Increasing demand for treatments targeting inherited and chronic diseases, alongside improvements in molecular delivery technologies, is expected to accelerate regional development of in vivo gene editing therapeutics.

Key players in the market

Some of the key players in the In Vivo Gene Editing Therapeutics Market include Intellia Therapeutics, Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Editas Medicine, Inc., Prime Medicine, Inc., Eli Lilly and Company, Precision BioSciences, Inc., Sangamo Therapeutics, Inc., Cellectis S.A., Metagenomi, Inc., Tessera Therapeutics, Inc., Arbor Biotechnologies, Inc., Mammoth Biosciences, Inc., Scribe Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Wave Life Sciences Ltd., Korro Bio, Inc., and Ensoma, Inc.

Key Developments:

In October 2026, Beam Therapeutics Inc. reported initial Phase 1/2 clinical results for BEAM-301, an investigational in vivo base editing therapy for glycogen storage disease type Ia. The company reported improvements in glucose control among patients receiving the 40 mg dose and continued enrollment in a higher-dose cohort.

In September 2026, Intellia Therapeutics, Inc. announced that the U.S. FDA had accepted its Biologics License Application for lonvoguran ziclumeran, an investigational in vivo CRISPR-based treatment for hereditary angioedema, granting Priority Review with a target decision date of March 10, 2027.

In August 2026, Precision BioSciences, Inc. reported progress in its Phase 1 ELIMINATE-B study of PBGENE-HBV, including liver biopsy evidence supporting the elimination of hepatitis B viral cccDNA using its ARCUS gene editing platform. The company also advanced patient recruitment for its FUNCTION-DMD clinical study.

Editing Technologies Covered:
• CRISPR-Cas Gene Editing
• Base Editing
• Prime Editing
• Zinc Finger Nucleases (ZFNs)
• Transcription Activator-Like Effector Nucleases (TALENs)
• Meganucleases & ARCUS Gene Editing
• Epigenome Editing
• Other Editing Technologies

Delivery Systems Covered:
• Lipid Nanoparticles (LNPs)
• Adeno-Associated Viral (AAV) Vectors
• Lentiviral & Other Viral Vectors
• Polymeric Nanoparticles
• Extracellular Vesicles & Exosomes
• Ligand-Conjugated Delivery Systems
• Other Delivery Systems

Therapeutic Approaches Covered:
• Gene Knockout & Disruption
• Gene Correction & Repair
• Gene Insertion & Replacement
• Gene Regulation & Epigenetic Modification
• Targeted Base Conversion
• Other Therapeutic Approaches

Applications Covered:
• Cardiovascular & Metabolic Disorders
• Hematological Disorders
• Neurological & Neuromuscular Disorders
• Ophthalmic Disorders
• Liver & Metabolic Genetic Diseases
• Infectious Diseases
• Oncology
• Other Applications

End Users Covered:
• Hospitals & Specialty Treatment Centers
• Academic Medical Centers
• Pharmaceutical & Biotechnology Companies
• Contract Research & Development Organizations
• Research Institutes
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances